Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports
Compose Response

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g.
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Statement of Competing Interests


  • Responses are moderated before posting and publication is at the absolute discretion of BMJ, however they are not peer-reviewed
  • Once published, you will not have the right to remove or edit your response. Removal or editing of responses is at BMJ's absolute discretion
  • If patients could recognise themselves, or anyone else could recognise a patient from your description, please obtain the patient's written consent to publication and send them to the editorial office before submitting your response [Patient consent forms]
  • By submitting this response you are agreeing to our full [Response terms and requirements]

Vertical Tabs

Other responses

Jump to comment:

  • Published on:
    Updated URL for reboxetine documents
    • Peter Doshi, Researcher University of Maryland School of Pharmacy

    The URL (link) to studies on reboxetine has changed. They are still housed by the Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (Institute for Quality and Efficiency in Healthcare = IQWiG), but now available at:

    Conflict of Interest:
    None declared.
  • Published on:
    Data available in Dryad
    Data for this article has been deposited in the Dryad digital repository. Please see:

    Doshi P, Jefferson T (2013) Data from: Clinical Study Reports of randomized controlled trials - an exploratory review of previously confidential industry reports. Dryad Digital Repository. doi:10.5061/dryad.331f7

    Peter Doshi
    Show More
    Conflict of Interest:
    None declared.